Change in number of dose-limiting side effects in kidney transplant recipients receiving valA vs. valG. [ Time Frame: 3 month and 1 year post-transplant ] [ Designated as safety issue: No ]ValG is associated with adverse events including diarrhea, fever, nausea, vomiting, tremor, leucopenia, neutropenia, anemia and thrombocytopenia in ???20% of patients.